{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:41:56Z","timestamp":1790048516762,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brain Canada Multi-Investigator Research Initiative"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bcp.2017.04.009","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T16:30:39Z","timestamp":1491841839000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Repurposing bacterial toxins for intracellular delivery of therapeutic proteins"],"prefix":"10.1016","volume":"142","author":[{"given":"Greg L.","family":"Beilhartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji N.","family":"Sugiman-Marangos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Melnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.04.009_b0010","unstructured":"FDA, Novel drugs 2015 Summary, in: C.o.D.E.a. Research (Ed.) 2016."},{"key":"10.1016\/j.bcp.2017.04.009_b0015","unstructured":"PharmaCompass, Top drugs by sales revenue in 2015: Who sold the biggest blockbuster drugs?, 2016. http:\/\/www.pharmacompass.com\/radio-compass-blog\/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugs. (Accessed February 23, 2017 2017)."},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1208\/s12248-015-9833-6","article-title":"Pharma success in product development-does biotechnology change the paradigm in product development and attrition","volume":"18","author":"Evens","year":"2016","journal-title":"AAPS J."},{"issue":"6220","key":"10.1016\/j.bcp.2017.04.009_b0025","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bcp.2017.04.009_b0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging the p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Khoo","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.04.009_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","article-title":"Peptides for nucleic acid delivery","author":"Lehto","year":"2016","journal-title":"Adv. Drug Deliv. Rev. 106(Pt A)"},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1389201015666140617092552","article-title":"Cell-penetrating peptide-based intelligent liposomal systems for enhanced drug delivery","volume":"15","author":"Gao","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"12","key":"10.1016\/j.bcp.2017.04.009_b0050","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.febslet.2013.04.031","article-title":"Cell-penetrating peptides: 20 years later, where do we stand?","volume":"587","author":"Bechara","year":"2013","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0055","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1248\/cpb.c16-00505","article-title":"Current understanding of direct translocation of arginine-rich cell-penetrating peptides and its internalization mechanisms","volume":"64","author":"Takeuchi","year":"2016","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"15","key":"10.1016\/j.bcp.2017.04.009_b0060","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1073\/pnas.0807883106","article-title":"Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins","volume":"106","author":"McNaughton","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.bcp.2017.04.009_b0065","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/ph3051456","article-title":"Building cell selectivity into CPP-mediated strategies","volume":"3","author":"Martin","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2017.04.009_b0070","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1021\/bc025517+","article-title":"Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides","volume":"13","author":"Niesner","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18388\/abp.2016_1275","article-title":"Virus-like particles as drug delivery vectors","volume":"63","author":"Zdanowicz","year":"2016","journal-title":"Acta Biochim. Pol."},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.bcp.2017.04.009_b0085","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1021\/nn201397z","article-title":"Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles","volume":"5","author":"Ashley","year":"2011","journal-title":"ACS Nano"},{"issue":"41","key":"10.1016\/j.bcp.2017.04.009_b0090","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1073\/pnas.1101874108","article-title":"Protein delivery using engineered virus-like particles","volume":"108","author":"Kaczmarczyk","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cbic.200400174","article-title":"Transport of surface-modified nanoparticles through cell monolayers","volume":"6","author":"Koch","year":"2005","journal-title":"ChemBioChem"},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.bcp.2017.04.009_b0110","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine (Lond)"},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles: applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bcp.2017.04.009_b0120","series-title":"Harnessing biomaterials for Nanomedicine: Preparation, toxicity and applications","article-title":"Adverse immune effects of liposomes: complement activation, immunogenicity and immune suppression","author":"Szebeni","year":"2009"},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomedicine"},{"issue":"13","key":"10.1016\/j.bcp.2017.04.009_b0130","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/S0021-9258(18)50491-9","article-title":"Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition","volume":"254","author":"Mekalanos","year":"1979","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0135","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/acschembio.6b00169","article-title":"Delivery of non-native cargo into mammalian cells using anthrax lethal toxin","volume":"11","author":"Rabideau","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2017.04.009_b0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2015.10.054","article-title":"Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity","author":"Dyer","year":"2015","journal-title":"J. Control Release 220(Pt A)"},{"issue":"16","key":"10.1016\/j.bcp.2017.04.009_b0145","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/cbic.201402290","article-title":"Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen","volume":"15","author":"Liao","year":"2014","journal-title":"ChemBioChem"},{"issue":"4","key":"10.1016\/j.bcp.2017.04.009_b0150","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2958.1995.tb02375.x","article-title":"Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus","volume":"15","author":"Milne","year":"1995","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.bcp.2017.04.009_b0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2014.12.019","article-title":"Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems","volume":"200","author":"Verdurmen","year":"2015","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0160","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1462-5822.2010.01480.x","article-title":"Imaging the cell entry of the anthrax oedema and lethal toxins with fluorescent protein chimeras","volume":"12","author":"Zornetta","year":"2010","journal-title":"Cell. Microbiol."},{"issue":"45","key":"10.1016\/j.bcp.2017.04.009_b0165","doi-asserted-by":"crossref","first-page":"15737","DOI":"10.1021\/bi981436i","article-title":"Characterization of membrane translocation by anthrax protective antigen","volume":"37","author":"Wesche","year":"1998","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0170","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1021\/acs.molpharmaceut.5b00233","article-title":"Efficient delivery of structurally diverse protein cargo into mammalian cells by a bacterial toxin","volume":"12","author":"Auger","year":"2015","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0175","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0021-9258(18)53890-4","article-title":"Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol","volume":"268","author":"Papini","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ab.2011.05.039","article-title":"Selective permeabilization for the high-throughput measurement of compartmented enzyme activities in mammalian cells","volume":"416","author":"Niklas","year":"2011","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0185","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cell.2011.08.046","article-title":"Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis","volume":"147","author":"Grebien","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0190","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.014050","article-title":"Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins","volume":"11","author":"Geiger","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","article-title":"One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell","volume":"15","author":"Yamaizumi","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2017.04.009_b0200","doi-asserted-by":"crossref","first-page":"D750","DOI":"10.1093\/nar\/gkp889","article-title":"BioNumbers\u2013the database of key numbers in molecular and cell biology","volume":"38","author":"Milo","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0205","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/prot.24628","article-title":"Cytotoxicity of the Vibrio vulnificus MARTX toxin effector DUF5 is linked to the C2A subdomain","volume":"82","author":"Antic","year":"2014","journal-title":"Proteins"},{"issue":"11","key":"10.1016\/j.bcp.2017.04.009_b0210","doi-asserted-by":"crossref","first-page":"e7946","DOI":"10.1371\/journal.pone.0007946","article-title":"Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CJI.0b013e3181ad4d5d","article-title":"Affitoxin\u2013a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors","volume":"32","author":"Zielinski","year":"2009","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0220","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/protein\/1.6.493","article-title":"Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein","volume":"1","author":"Williams","year":"1987","journal-title":"Protein Eng."},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0225","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/protein\/4.8.989","article-title":"Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein","volume":"4","author":"Jean","year":"1991","journal-title":"Protein Eng."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00088-12","article-title":"Changing the receptor specificity of anthrax toxin","volume":"3","author":"Mechaly","year":"2012","journal-title":"MBio"},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0235","first-page":"1834","article-title":"A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells","volume":"63","author":"Liu","year":"2003","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0240","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/bc034111+","article-title":"Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells","volume":"14","author":"Liu","year":"2003","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0245","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.123711","article-title":"Resimmune, an anti-CD3epsilon recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma","volume":"100","author":"Frankel","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bcp.2017.04.009_b0250","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.leukres.2009.02.006","article-title":"Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy","volume":"33","author":"Vallera","year":"2009","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/j.bcp.2017.04.009_b0255","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0260","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcb.1982.240180107","article-title":"The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes","volume":"18","author":"Sly","year":"1982","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2017.04.009_b0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"16","key":"10.1016\/j.bcp.2017.04.009_b0275","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.bcp.2017.04.009_b0280","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0285","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","article-title":"Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor","volume":"17","author":"Coloma","year":"2000","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.bcp.2017.04.009_b0290","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/bit.22135","article-title":"Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse","volume":"102","author":"Boado","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bcp.2017.04.009_b0295","doi-asserted-by":"crossref","unstructured":"P.J. Gaillard, A. Brink, A.G. de Boer, Diphtheria toxin receptor-targeted brain drug delivery, International Congress Series 1277(Drug Transport(ers) and the Diseased Brain) (2005) 185\u2013198.","DOI":"10.1016\/j.ics.2005.02.022"},{"issue":"5920","key":"10.1016\/j.bcp.2017.04.009_b0300","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.1164139","article-title":"Selective erasure of a fear memory","volume":"323","author":"Han","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0305","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3171\/jns.1990.72.6.0946","article-title":"Diphtheria toxin effects on brain-tumor xenografts. Implications for protein-based brain-tumor chemotherapy","volume":"72","author":"Wrobel","year":"1990","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","article-title":"Intrathecal delivery of protein therapeutics to the brain: a critical reassessment","volume":"144","author":"Calias","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2017.04.009_b0315","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bcp.2017.04.009_b0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ceb.2015.05.005","article-title":"Effects of endocytosis on receptor-mediated signaling","volume":"35","author":"Irannejad","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0325","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/membranes4030424","article-title":"The mysterious ways of ErbB2\/HER2 trafficking","volume":"4","author":"Bertelsen","year":"2014","journal-title":"Membranes (Basel)"},{"key":"10.1016\/j.bcp.2017.04.009_b0330","doi-asserted-by":"crossref","first-page":"31878","DOI":"10.1038\/srep31878","article-title":"High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries","volume":"6","author":"Hou","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2017.04.009_b0335","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2004-01-0339","article-title":"A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts","volume":"104","author":"Abi-Habib","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2017.04.009_b0340","doi-asserted-by":"crossref","first-page":"17976","DOI":"10.1074\/jbc.M011085200","article-title":"Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin","volume":"276","author":"Liu","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2017.04.009_b0345","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013219","article-title":"Disulfide bond formation in the mammalian endoplasmic reticulum","volume":"4","author":"Bulleid","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2017.04.009_b0350","unstructured":"USFAD Administration, Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products, in: O.o.M.P. Division of Medical Policy Development, Center for Drug Evaluation and Research (CDER) (Ed.) 2014."},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0355","first-page":"110","article-title":"DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma","volume":"1","author":"Foss","year":"2000"},{"key":"10.1016\/j.bcp.2017.04.009_b0360","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.sbi.2016.06.003","article-title":"Design and engineering of deimmunized biotherapeutics","volume":"39","author":"Griswold","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"19","key":"10.1016\/j.bcp.2017.04.009_b0365","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0264-410X(98)00173-X","article-title":"Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix","volume":"16","author":"Schafer","year":"1998","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.bcp.2017.04.009_b0370","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/cmb.2012.0251","article-title":"Structure-guided deimmunization of therapeutic proteins","volume":"20","author":"Parker","year":"2013","journal-title":"J. Comput. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0375","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/toxins7104067","article-title":"Mutagenic deimmunization of diphtheria toxin for use in biologic drug development","volume":"7","author":"Schmohl","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"8","key":"10.1016\/j.bcp.2017.04.009_b0380","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0385","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"issue":"208","key":"10.1016\/j.bcp.2017.04.009_b0390","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0395","doi-asserted-by":"crossref","first-page":"e54290","DOI":"10.1371\/journal.pone.0054290","article-title":"High-resolution analysis and functional mapping of cleavage sites and substrate proteins of furin in the human proteome","volume":"8","author":"Shiryaev","year":"2013","journal-title":"PLoS ONE"},{"issue":"27","key":"10.1016\/j.bcp.2017.04.009_b0400","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1016\/S0021-9258(17)32431-6","article-title":"Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver","volume":"269","author":"Chiron","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2017.04.009_b0405","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1073\/pnas.1400680111","article-title":"Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0410","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0415","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cell.2015.03.028","article-title":"Efficient intracellular delivery of native proteins","volume":"161","author":"D'Astolfo","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0420","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0092-8674(92)90623-K","article-title":"Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor","volume":"69","author":"Naglich","year":"1992","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.bcp.2017.04.009_b0425","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1016\/S0021-9258(18)42291-0","article-title":"The alpha 2-macroglobulin receptor\/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A","volume":"267","author":"Kounnas","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.bcp.2017.04.009_b0430","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1073\/pnas.0405405101","article-title":"Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation","volume":"101","author":"Lacy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6375","key":"10.1016\/j.bcp.2017.04.009_b0435","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/357216a0","article-title":"The crystal structure of diphtheria toxin","volume":"357","author":"Choe","year":"1992","journal-title":"Nature"},{"issue":"7553","key":"10.1016\/j.bcp.2017.04.009_b0440","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nature14247","article-title":"Atomic structure of anthrax protective antigen pore elucidates toxin translocation","volume":"521","author":"Jiang","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0445","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1365-2958.1991.tb00796.x","article-title":"Anthrax toxin protective antigen: low-pH-induced hydrophobicity and channel formation in liposomes","volume":"5","author":"Koehler","year":"1991","journal-title":"Mol. Microbiol."},{"issue":"3","key":"10.1016\/j.bcp.2017.04.009_b0450","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2958.1997.tb02669.x","article-title":"Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery","volume":"23","author":"Lemichez","year":"1997","journal-title":"Mol. Microbiol."},{"issue":"5735","key":"10.1016\/j.bcp.2017.04.009_b0455","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1113380","article-title":"A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore","volume":"309","author":"Krantz","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2017.04.009_b0460","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.87.1.308","article-title":"Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity","volume":"87","author":"Chaudhary","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.bcp.2017.04.009_b0465","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0092-8674(01)00289-6","article-title":"Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin","volume":"104","author":"Tsai","year":"2001","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2017.04.009_b0470","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1128\/IAI.05503-11","article-title":"Structural and functional interactions between the cholera toxin A1 subunit and ERdj3\/HEDJ, a chaperone of the endoplasmic reticulum","volume":"79","author":"Massey","year":"2011","journal-title":"Infect. Immun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T10:50:24Z","timestamp":1658919024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217301983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":94,"alternative-id":["S0006295217301983"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.04.009","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing bacterial toxins for intracellular delivery of therapeutic proteins","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}